Table 2.
Laboratory parameters in different groups.
| Characteristics | Non-DIC, n = 48 | DIC, n = 34 | p |
|---|---|---|---|
| 28-day mortality, n (%) | 3 (6.3) | 17 (50) | <0.0001**** |
| ICU stay time, days | 11.3 (3.2–19.4) | 15.3 (7.2–23.3) | 0.0350* |
| APACHE II | 16.7 (11.1–22.3) | 20.4 (13.4–27.5) | 0.0107* |
| SOFA | 8.0 (4.1–11.9) | 11.2 (7.2–15.2) | 0.0005*** |
| MV duration | 81 (0–92) | 157 (75–218) | 0.0009*** |
| CRRT | 3 (6.3) | 8 (23.5) | 0.0237* |
| PCT | 2.0 (0.5–7.3) | 5.0 (2.9–21.0) | 0.34 |
| CRP | 145.2 (36.8–187.3) | 264.6 (125.1–351.1) | <0.0001**** |
| DIC score | 3.0 (2.0–4.0) | 5.0 (5.0–7.0) | <0.0001**** |
| PLT, *109/L | 170.9 (59.7–282.1) | 73.7 (24.3–123.1) | <0.0001**** |
| PT, s | 17.0 (10.8–23.3) | 22.9 (11.9–34.0) | 0.0031** |
| Fbg, g/L | 3.8 (2.2–5.4) | 2.8 (1.6–3.9) | 0.0015** |
| D-Dimer, mg/L FEU | 4.3 (2.3–8.7) | 16.9 (8.3–23.2) | 0.0002*** |
| Thrombotic events | 9 (18.8) | 15 (44) | 0.0156* |
| Hemorrhagic events | 7 (14.6) | 11 (32.4) | 0.0643 |
| Blood transfusion | |||
| RBC | 23 (47.9) | 24 (70.6) | 0.0456* |
| Plasma | 16 (33.3) | 27 (79.4) | <0.0001**** |
| PLT | 4 (8.3) | 10 (29.4) | 0.0174* |
| ELA2, pg/ml | 1,247 (869–1,625) | 2,039 (1,544–2,534) | <0.0001**** |
| H3, pg/ml | 140 (47–233) | 307 (199–415) | <0.0001**** |
| Syn, pg/ml | 91 (42–141) | 162 (108–215) | <0.0001**** |
DIC, disseminated intravascular coagulation; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; MV, mechanical ventilation; CRRT, continuous renal replacement therapy; PCT, procalcitonin; CRP, C-reactive protein; PLT, platelet; PT, prothrombin time; Fbg, fibrinogen; RBC, red blood cell; ELA2, neutrophil elastase 2; H3, citrullinated histone H3; Syn, syndecan-1.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.